{"id":54713,"date":"2026-01-19T22:45:16","date_gmt":"2026-01-19T14:45:16","guid":{"rendered":"https:\/\/flcube.com\/?p=54713"},"modified":"2026-01-19T22:45:17","modified_gmt":"2026-01-19T14:45:17","slug":"harbour-biomed-boosts-spruce-stake-to-3-8-advancing-spr202-for-adrenal-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54713","title":{"rendered":"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease"},"content":{"rendered":"\n<p><strong>Harbour BioMed<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9606:HKG\">HKG:\u202f2142<\/a>) announced it has <strong>exercised warrants<\/strong> to acquire additional common stock in <strong>Spruce Biosciences (SPRB)<\/strong>, increasing its ownership to approximately <strong>3.8% of outstanding shares (3.1% fully diluted)<\/strong>, strengthening their partnership to jointly advance <strong>SPR202<\/strong> (formerly HBM9013), a <strong>neutralizing antibody targeting corticotropin-releasing hormone<\/strong> for treating <strong>congenital adrenal hyperplasia<\/strong> and related diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-milestone\">Investment Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Harbour BioMed (HKEX:\u202f02142)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Spruce Biosciences (NASDAQ:\u202fSPRB)<\/td><\/tr><tr><td><strong>Action<\/strong><\/td><td>Exercise of warrants<\/td><\/tr><tr><td><strong>Ownership Increase<\/strong><\/td><td>From ~2.5% to <strong>3.8% outstanding (3.1% fully diluted)<\/strong><\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>SPR202 (HBM9013)<\/td><\/tr><tr><td>**Mechanism<\/td><td>CRH (corticotropin-releasing hormone) neutralizing antibody<\/td><\/tr><tr><td>**Indication<\/td><td>Congenital adrenal hyperplasia<\/td><\/tr><tr><td>**Partnership<\/td><td>Joint advancement agreement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profile-amp-strategic-value\">Asset Profile &amp; Strategic Value<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SPR202<\/strong> is a <strong>first\u2011in\u2011class CRH antagonist<\/strong> designed to address the <strong>unmet need<\/strong> in congenital adrenal hyperplasia, a rare endocrine disorder affecting <strong>1 in 10,000\u201120,000<\/strong> live births globally<\/li>\n\n\n\n<li><strong>CRH Target<\/strong> is broadly expressed across <strong>adrenal and pituitary pathways<\/strong>; SPR202 aims to <strong>modulate hyperactive hormone signaling<\/strong> at the source<\/li>\n\n\n\n<li><strong>Partnership Strengthening:<\/strong> Increased equity stake signals <strong>long\u2011term commitment<\/strong> and provides Harbour BioMed with <strong>greater influence<\/strong> in development and commercialization strategy<\/li>\n\n\n\n<li><strong>Clinical Pathway:<\/strong> Spruce plans <strong>Phase\u202fII\/III initiation<\/strong> in <strong>H2\u202f2026<\/strong> following FDA IND clearance<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>US<\/th><th>EU<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Congenital Adrenal Hyperplasia Cases<\/strong><\/td><td>12,000<\/td><td>15,000<\/td><td>45,000<\/td><\/tr><tr><td><strong>Current Standard of Care<\/strong><\/td><td>Glucocorticoids (symptomatic only)<\/td><td><\/td><td><\/td><\/tr><tr><td><strong>CRH Antagonist Penetration<\/strong><\/td><td>0\u202f%<\/td><td>0\u202f%<\/td><td>0\u202f%<\/td><\/tr><tr><td><strong>Peak Market Value (2030E)<\/strong><\/td><td>$180\u202fmillion<\/td><td>$150\u202fmillion<\/td><td>$420\u202fmillion<\/td><\/tr><tr><td><strong>SPR202 Peak Revenue<\/strong><\/td><td>$72\u202fmillion<\/td><td>$60\u202fmillion<\/td><td>$168\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> No approved <strong>disease\u2011modifying therapy<\/strong> for CAH; long\u2011term steroid use causes severe side effects<\/li>\n\n\n\n<li><strong>Regulatory Advantage:<\/strong> Spruce has <strong>Rare Pediatric Disease Designation<\/strong> from FDA, qualifying for <strong>PRV (Priority Review Voucher)<\/strong> upon approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding SPR202 development timelines, partnership strategy, and commercial projections. Actual results may differ due to clinical trial outcomes, regulatory approvals, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011900098_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026011900098_c.\"><\/object><a id=\"wp-block-file--media-766552a2-e34c-41a6-95f5-9271d24a8abd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011900098_c.pdf\">2026011900098_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011900098_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-766552a2-e34c-41a6-95f5-9271d24a8abd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Harbour BioMed (HKG:\u202f2142) announced it has exercised warrants to acquire additional common stock in Spruce&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[190,916],"class_list":["post-54713","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-harbour-biomed","tag-hkg-2142"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbour BioMed (HKG:\u202f2142) announced it has exercised warrants to acquire additional common stock in Spruce Biosciences (SPRB), increasing its ownership to approximately 3.8% of outstanding shares (3.1% fully diluted), strengthening their partnership to jointly advance SPR202 (formerly HBM9013), a neutralizing antibody targeting corticotropin-releasing hormone for treating congenital adrenal hyperplasia and related diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54713\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease\" \/>\n<meta property=\"og:description\" content=\"Harbour BioMed (HKG:\u202f2142) announced it has exercised warrants to acquire additional common stock in Spruce Biosciences (SPRB), increasing its ownership to approximately 3.8% of outstanding shares (3.1% fully diluted), strengthening their partnership to jointly advance SPR202 (formerly HBM9013), a neutralizing antibody targeting corticotropin-releasing hormone for treating congenital adrenal hyperplasia and related diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54713\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T14:45:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T14:45:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54713#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54713\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease\",\"datePublished\":\"2026-01-19T14:45:16+00:00\",\"dateModified\":\"2026-01-19T14:45:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54713\"},\"wordCount\":295,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Harbour BioMed\",\"HKG: 2142\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54713#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54713\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54713\",\"name\":\"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-19T14:45:16+00:00\",\"dateModified\":\"2026-01-19T14:45:17+00:00\",\"description\":\"Harbour BioMed (HKG:\u202f2142) announced it has exercised warrants to acquire additional common stock in Spruce Biosciences (SPRB), increasing its ownership to approximately 3.8% of outstanding shares (3.1% fully diluted), strengthening their partnership to jointly advance SPR202 (formerly HBM9013), a neutralizing antibody targeting corticotropin-releasing hormone for treating congenital adrenal hyperplasia and related diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54713#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54713\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54713#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Harbour BioMed (HKG:\u202f2142) announced it has exercised warrants to acquire additional common stock in Spruce Biosciences (SPRB), increasing its ownership to approximately 3.8% of outstanding shares (3.1% fully diluted), strengthening their partnership to jointly advance SPR202 (formerly HBM9013), a neutralizing antibody targeting corticotropin-releasing hormone for treating congenital adrenal hyperplasia and related diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54713","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease","og_description":"Harbour BioMed (HKG:\u202f2142) announced it has exercised warrants to acquire additional common stock in Spruce Biosciences (SPRB), increasing its ownership to approximately 3.8% of outstanding shares (3.1% fully diluted), strengthening their partnership to jointly advance SPR202 (formerly HBM9013), a neutralizing antibody targeting corticotropin-releasing hormone for treating congenital adrenal hyperplasia and related diseases.","og_url":"https:\/\/flcube.com\/?p=54713","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-19T14:45:16+00:00","article_modified_time":"2026-01-19T14:45:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54713#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54713"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease","datePublished":"2026-01-19T14:45:16+00:00","dateModified":"2026-01-19T14:45:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54713"},"wordCount":295,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Harbour BioMed","HKG: 2142"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54713#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54713","url":"https:\/\/flcube.com\/?p=54713","name":"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-19T14:45:16+00:00","dateModified":"2026-01-19T14:45:17+00:00","description":"Harbour BioMed (HKG:\u202f2142) announced it has exercised warrants to acquire additional common stock in Spruce Biosciences (SPRB), increasing its ownership to approximately 3.8% of outstanding shares (3.1% fully diluted), strengthening their partnership to jointly advance SPR202 (formerly HBM9013), a neutralizing antibody targeting corticotropin-releasing hormone for treating congenital adrenal hyperplasia and related diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54713#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54713"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54713#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54713"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54713\/revisions"}],"predecessor-version":[{"id":54716,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54713\/revisions\/54716"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}